CD28-mediated regulation of multiple myeloma cell proliferation and survival

Blood

Volumn 109, Issue 11, 2007, Pages 5002-5010

  Bahlis, Nizar J ^a,b   King, Anne M ^a   Kolonias, Despina ^a   Carlson, Louise M ^a,b   Hong, Yu Liu ^a   Hussein, Mohamad A ^c   Terebelo, Howard R ^d   Byrne Jr , Gerald E ^a   Levine, Bruce L ^e   Boise, Lawrence H ^a,b   Lee, Kelvin P ^a,b,f  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d PROVIDENCE HOSPITAL   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY CD28; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL DEATH; CELL INFILTRATION; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 34249671217     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-03-012542     Document Type: Article

References (76)

1. Dalton WS, Bergsagel PL, Kuehl WM, Anderson KC, Harousseau JL. Multiple myeloma. Am Soc Hematol Education Program. 2001;157-177.
2. Lokhorst HM, Sonneveld P, Verdonck LF. Intensive treatment for multiple myeloma: where do we stand? Br J Haematol. 1999;106:18-27.
3. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A. 2001;98:11581-11586.
4. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93:1658-1667.
5. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAMDR). Oncogene. 2000;19:4319-4327.
6. Landowski TH, Olashaw NE, Agrawal D, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene. 2003;22:2417-2421.
7. Sanz-Rodriguez F, Teixido J. VLA-4-dependent myeloma cell adhesion. Leuk Lymphoma. 2001;41:239-245.
8. Yaccoby S, Wezeman MJ, Henderson A, et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004;64:2016-2023.
9. Tricot G, Barlogie B, Van Rhee F. Treatment advances in multiple myeloma. Br J Haematol. 2004;125:24-30.
10. Kozbor D, Moretta A, Messner HA, Moretta L, Croce CM. Tp44 molecules involved in antigen-independent T-cell activation are expressed on human plasma cells. J Immunol. 1987;138:4128-4132.
11. Lee KP, Taylor C, Petryniak B, et al. The genomic organization of the CD28 gene: implications for the regulation of CD28 mRNA expression and heterogeneity. J Immunol. 1990;145:344-352.
12. Robillard N, Jego G, Pellat-Deceunynck C, et al. CD28, a marker associated with tumoral expansion in multiple myeloma. Clin Cancer Res. 1998;4:1521-1526.
13. Kornbluth J. Potential role of CD28-B7 interactions in the growth of myeloma plasma cells. Curr Top Microbiol Immunol.1995;194:43-49.
14. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2:116-126.
15. Rudd CE, Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol. 2003;3:544-556.
16. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res. 2000;60:6763-6770.
17. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002;21:5673-5683.
18. Shahinian A, Pfeffer K, Lee KP, et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993;261:609-612.
19. Lindstein T, June CH, Ledbetter JA, Stella G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science. 1989;244:339-343.
20. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity.1995;3:87-98.
21. Frauwirth KA, Riley JL, Harris MH, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002;16:769-777.
22. Shapiro VS, Mollenauer MN, Weiss A. Endogenous CD28 expressed on myeloma cells upregulates interleukin-8 production: implications for multiple myeloma progression. Blood. 2001;98:187-193.
23. Almeida J, Orfao A, Ocqueteau M, et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol. 1999;107:121-131.
24. Mateo G, Gutierrez N, Lopez-Berges MC, et al. Immunophenotype of the malignant clone: implications for management. Haematologica. 2005;90(S1):3.
25. Pope B, Brown RD, Gibson J, Yuen E, Joshua D. B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy. Blood. 2000;96:1274-1279.
26. Zhang XG, Olive D, Devos J, et al. Malignant plasma cell lines express a functional CD28 molecule. Leukemia. 1998;12:610-618.
27. Lorre K, Kasran A, Van Vaeck F, de Boer M, Ceuppens JL. Interleukin-1 and B7/CD28 interaction regulate interleukin-6 production by human T cells. Clin Immunol Immunopathol. 1994;70:81-90.
28. Horspool JH, Perrin PJ, Woodcock JB et al. Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4. J Immunol. 1998;160:2706-2714.
29. Gray PK, Stephan RP, Apilado RG, et al. Expression of CD28 by bone marrow stromal cells and its involvement in B lymphopoiesis. J Immunol. 2002;169:2292-2302.
30. Qiu YH, Sun ZW, Shi Q, et al. Apoptosis of multiple myeloma cells induced by agonist monoclonal antibody against human CD28. Cell Immunol. 2005;236:154-160.
31. Corthay A, Skovseth DK, Lundin KU, et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity. 2005;22:371-383.
32. Rettig MB, Ma HJ, Vescio RA, et al. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science. 1997;276:1851-1854.
33. June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB. T-cell proliferation involving the CD28 pathway is associated with cyclosporine- resistant interleukin 2 gene expression. Mol Cell Biol. 1987;7:4472-4481.
34. Levine BL, Ueda Y, Craighead N, Huang ML, June CH. CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. Int Immunol. 1995;7:891-904.
35. Lindner I, Kharfan-Dabaja MA, Ayala E, et al. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL. J Immunol. 2003;171:1780-191.
36. St. Louis DC, Woodcock JB, Franzoso G, et al. Evidence for distinct intracellular signaling pathways in CD34+ progenitor to dendritic cell differentiation from a human cell line model. J Immunol. 1999;162:3237-3248.
37. Schlienger K, Craighead N, Lee KP, Levine BL, June CH. Efficient priming of protein antigenspecific human CD4(+) T cells by monocyte-derived dendritic cells. Blood. 2000;96:3490-3498.
38. Coligan JE, ed. Current Protocols in Immunology. New York: John Wiley and Sons; 1996.
39. Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002;109:295-299.
40. Cejas PJ, Carlson LM, Kolonias D, et al. Regulation of RelB expression during the initiation of dendritic cell differentiation. Mol Cell Biol. 2005;25:7900-7916.
41. Burr JS, Savage ND, Messah GE, et al. Cutting edge: distinct motifs within CD28 regulate T cell proliferation and induction of Bcl-XL. J Immunol. 2001;166:5331-5335.
42. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639-16647.
43. Harrington EA, Bennett MR, Fanidi A, Evan GI. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 1994;13:3286-3295.
44. Said JW, Rettig MR, Heppner K, et al. Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma. Blood. 1997;90:4278-4282.
45. Bros M, Ross XL, Pautz A, Reske-Kunz AB, Ross R. The human fascin gene promoter is highly active in mature dendritic cells due to a stage-specific enhancer. J Immunol. 2003;171:1825-1834.
46. Pinkus GS, Lones MA, Matsumura F, et al. Langerhans cell histiocytosis immunohistochemical expression of fascin, a dendritic cell marker. Am J Clin Pathol. 2002;118:335-343.
47. Pinkus GS, Pinkus JL, Langhoff E, et al. Fascin, a sensitive new marker for Reed-Sternberg cells of Hodgkin's disease: evidence for a dendritic or B cell derivation? Am J Pathol. 1997;150:543-562.
48. Vakkila J, Lotze MT, Riga C, Jaffe R. A basis for distinguishing cultured dendritic cells and macrophages in cytospins and fixed sections. Pediatr Dev Pathol. 2005;8:43-51.
49. Ackerman AL, Cresswell P. Regulation of MHC class I transport in human dendritic cells and the dendritic-like cell line KG-1. J Immunol. 2003;170:4178-4188.
50. Li J, Mbow ML, Sun L, et al. Induction of dendritic cell maturation by IL-18. Cell Immunol. 2004;227:103-108.
51. Hajas G, Zsiros E, Laszlo T, et al. New phenotypic, functional and electrophysiological characteristics of KG-1 cells. Immunol Lett. 2004;92:97-106.
52. Suciu-Foca CN, Piazza F, Ho E, et al. Distinct mRNA microarray profiles of tolerogenic dendritic cells. Hum Immunol. 2001;62:1065-1072.
53. Hulette BC, Rowden G, Ryan CA, et al. Cytokine induction of a human acute myelogenous leukemia cell line (KG-1) to a CD1a+ dendritic cell phenotype. Arch Dermatol Res. 2001;293:147-158.
54. Wang Y, Kelly CG, Karttunen JT, et al. CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines. Immunity. 2001;15:971-983.
55. Soilleux EJ, Barten R, Trowsdale J. DC-SIGN, a related gene, DC-SIGNR, and CD23 form a cluster on 19p13. J Immunol. 2000;165:2937-2942.
56. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
57. Harhaj EW, Sun SC. IkappaB kinases serve as a target of CD28 signaling. J Biol Chem. 1998;273:25185-25190.
58. Luhder F, Huang Y, Dennehy KM, et al. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med. 2003;197:955-966.
59. Ghosh P, Buchholz MA, Yano S, Taub D, Longo DL. Effect of rapamycin on the cyclosporin A - resistant CD28-mediated costimulatory pathway. Blood. 2002;99:4517-4524.
60. Stromberg T, Dimberg A, Hammarberg A, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood. 2004;103:3138-3147.
61. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood. 2002;99:4079-4086.
62. LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004;103:1787-1790.
63. Linette GP, Li Y, Roth K, Korsmeyer SJ. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc Natl Acad Sci U S A. 1996;93:9545-9552.
64. Zhou LJ, Tedder TF. A distinct pattern of cytokine gene expression by human CD83+ blood dendritic cells. Blood. 1995;86:3295-3301.
65. Santiago-Schwarz F, Tucci J, Carsons SE. Endogenously produced interleukin 6 is an accessory cytokine for dendritic cell hematopoiesis. Stem Cells. 1996;14:225-231.
66. Kushnir N, Liu L, MacPherson GG. Dendritic cells and resting B cells form clusters in vitro and in vivo: T cell independence, partial LFA-1 dependence, and regulation by cross-linking surface molecules. J Immunol. 1998;160:1774-1781.
67. Wykes M, MacPherson G. Dendritic cell-B-cell interaction: dendritic cells provide B cells with CD40-independent proliferation signals and CD40-dependent survival signals. Immunology. 2000;100:1-3.
68. Fayette J, Durand I, Bridon JM, et al. Dendritic cells enhance the differentiation of naive B cells into plasma cells in vitro. Scand J Immunol. 1998;48:563-570.
69. Dubois B, Massacrier C, Vanbervliet B, et al. Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes. J Immunol. 1998;161:2223-2231.
70. Dubois B, Barthelemy C, Durand I, et al. Toward a role of dendritic cells in the germinal center reaction: triggering of B cell proliferation and isotype switching. J Immunol. 1999;162:3428-3436.
71. Balazs M, Martin F, Zhou T, Kearney J. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity. 2002;17:341-352.
72. Kukreja A, Hutchinson A, Dhodapkar K, et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med. 2006;203:1859-1865.
73. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin-6 deprivation and dexamethasone. Blood. 2004;103:3148-3157.
74. Deng L, Ding W, Granstein RD. Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells. J Invest Dermatol. 2003;121:1060-1065.
75. Mohty M, Stoppa AM, Blaise D, et al. Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide. J Leukoc Biol. 2002;72:939-945.
76. Nencioni A, Garuti A, Schwarzenberg K, et al. Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol. 2006;36:681-689.